Liminatus Pharma, Inc. (LIMNW) stock
LIMNWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMN
$0.04+0.00 (0.00%)
Close on Oct 30, 2026Market cap $189.39MP/E –Yield –
Liminatus Pharma net income
Net income is the profit left for shareholders after every expense, interest and tax.
Liminatus Pharma's net income for the twelve months ending Jun 30, 2026 was -$12.52M. For fiscal 2025 it was -$10.21M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.21M | – |
| FY2024 | Dec 31, 2024 | -$3.55M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.41M | -1342.2% |
| Q1 FY2026 | Mar 31, 2026 | -$1.12M | – |
| Q4 FY2025 | Dec 31, 2025 | -$8.17M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.82M | – |
| Q2 FY2025 | Jun 30, 2025 | $113.29K | – |
| Q1 FY2025 | Mar 31, 2025 | -$327.53K | – |
| Q4 FY2024 | Dec 31, 2024 | -$229.75K | – |
| Q3 FY2024 | Sep 30, 2024 | -$601.37K | – |
| Q2 FY2024 | Jun 30, 2024 | -$961.21K | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.75M | – |